CD8A and neoplasm: The mechanism of action of TKIs targeting FLT3 may not only involved in direct tumor cell killing, but also in increased interleukin-15, leadings to an increase in CD8+CD107a+IFN-γ+ T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which could eradicate leukemia in secondary recipients (146).